Drug intelligence / Profile preview

ACT-20-CM

Development stage: Phase 2
Lead developer: Aspire Health Science
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

ACT-20-CM is a cell therapy product under development for the treatment of moderate to severe COVID-19 pneumonia. It is administered intravenously and utilizes stem cell therapy as its primary mechanism of action. The product has been evaluated in clinical trials, including a Phase 2 study, but has not received regulatory approval in any country. There are no known adverse events reported to date. The developer and main company associated with this drug is Aspire Health Science[1][2].

Brand names: ACT-20-CMACT20-CMACT 20-CM
Other names: ACT-20-CMACT20-CMACT 20-CM

Targets

CXCR4 (C-X-C motif chemokine receptor 4)IGF-1R (Insulin-like growth factor 1 receptor)MET (Mesenchymal-epithelial transition factor receptor)VEGFR (VEGFR family)

Beyond the preview

Go deeper on ACT-20-CM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT-20-CM.

Explore the full profile